<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553006</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-EC-PE-5-036/54</org_study_id>
    <nct_id>NCT01553006</nct_id>
  </id_info>
  <brief_title>Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis</brief_title>
  <acronym>RS</acronym>
  <official_title>A Comparison of Cefditoren Pivoxil 10 mg/kg/Day and Cefditoren Pivoxil 20 mg/kg/Day in Treatment of Childhood With Acute Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cefditoren pivoxil has been used in rhinosinusitis treatment. However, little is known about
      the efficacy of this drug at low and high doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation was a randomized, investigator-blinded, and parallel study, conducted in
      patients (age 1-15 years) with acute rhinosinusitis. Two groups of patients were randomized
      received low (10 MKD) or high (20 MKD) of drug for 14 days. Changes in sinus symptoms scores,
      response rate and adverse effect were evaluated at days 7 and 14. Relapse rate was recorded
      at days 21 and 28. Recurrence of sinus symptoms at day 60 were assessed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sinus symptoms scores</measure>
    <time_frame>14 days</time_frame>
    <description>Change of sinus sympotms scores from baseline in 2 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>at day 28</time_frame>
    <description>The relapse rate of sinus symptoms scores at day 28.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>cefditoren pivoxil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefditoren 10 mg/kg/day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cefditoren pivoxil high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cefditoren 20 MKD were used to compare efficacy of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefditoren pivoxil</intervention_name>
    <description>comparison of different dosages of cefditoren pivoxil</description>
    <arm_group_label>cefditoren pivoxil</arm_group_label>
    <arm_group_label>cefditoren pivoxil high dose</arm_group_label>
    <other_name>Meiact</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children age 1-15 years old diagnosed acute rhinosinusitis

        Exclusion Criteria:

          -  poor compliance

          -  other infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orapan Poachanukoon, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thammasat University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thammasat University</name>
      <address>
        <city>Prathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orapan Poachanukoon, MD.</last_name>
      <phone>66819316781</phone>
      <email>orapanpoachanukoon@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Orapan Poachanukoon</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>rhinosinusitis</keyword>
  <keyword>cefditoren pivoxil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefditoren</mesh_term>
    <mesh_term>Cefditoren pivoxil</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

